12:00 AM
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VS-6063: Phase II start

This quarter, Verastem will begin a double-blind, placebo-controlled, international, pivotal Phase II trial to evaluate 400 mg oral VS-6063 twice daily in 350-400 patients. This quarter, Verastem also plans to start a Phase II trial of VS-6063 in K-Ras-mutated...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >